TY - JOUR T1 - A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin JF - medRxiv DO - 10.1101/2020.08.23.20180489 SP - 2020.08.23.20180489 AU - Juan Kou AU - Yingying Zhang AU - Feng Zhou AU - Cornelia Sindermann AU - Christian Montag AU - Benjamin Becker AU - Keith M Kendrick Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180489.abstract N2 - Background The neuropeptide oxytocin is proposed as a promising therapy for social dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical trials report some benefits of chronic treatment it is unclear whether efficacy may be influenced by dose frequency or genotype.Methods In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150 male subjects) we investigated acute and different chronic (every day or on alternate days for 5 days) intranasal oxytocin (24IU) effects and oxytocin receptor genotype-mediated treatment sensitivity on amygdala responses to face emotions. We also investigated similar effects on resting state functional connectivity between the amygdala and prefrontal cortex.Results A single dose of oxytocin reduced amygdala responses to all face emotions but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of rs53576 and A carriers of rs2254298. The effects of oxytocin on resting state functional connectivity were not influenced by either dose-frequency or receptor genotype.Conclusions Infrequent chronic oxytocin administration may be therapeutically most efficient and its anxiolytic neural and behavioral actions are highly genotype-dependent in males.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03610919Funding StatementThis project was supported by National Natural Science Foundation of China (NSFC) grant numbers 31530032 (KMK) and 91632117 (BB)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee (Institutional Review Board, University of Electronic Science and Technology of China)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript will be available ER -